Case Report: Secondary Amenorrhea with Hyperprolactinemia due to Pituitary Macroadenoma

Authors

  • Annissa Febriani Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya/ Saiful Anwar General Hospital, Malang, East Java, Indonesia https://orcid.org/0000-0002-3997-3761
  • Donny Wisnu Wardhana Department of Neurosurgeon, Faculty of Medicine, University of Brawijaya East Java, Malang, East Java, 65145, Indonesia
  • Nugrahanti Prasetyorini Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya/ Saiful Anwar General Hospital, Malang, East Java, Indonesia
  • Pande Made Dwijayasa Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya/ Saiful Anwar General Hospital, Malang, East Java, Indonesia

DOI:

https://doi.org/10.55561/ajhr.v1i2.19

Keywords:

Keywords: hyperprolactinemia; pituitary macroadenoma; dopamine agonist

Abstract

Introduction: Secondary amenorrhea has a broad etiology, so each case must be studied in depth. One of the causes of secondary amenorrhea is a state of hyperprolactinemia caused by a mass in the anterior pituitary. Pituitary macroadenoma patients may be asymptomatic or have a hormone imbalance or mass impact symptoms. Tumors in asymptomatic patients might be identified during a routine head imaging examination for unrelated medical issues.

Case Presentation: A 24-year-old unmarried woman with complaints of headache, blurred vision, and worsening for one year ago. The patient complained of not having menstruation in the past five years ago, with a history of previous normal menstruation. On physical examination, found breast and pubic Tanner stage 5. On laboratory examination, it was found FSH (2.21), Oestradiol (20.23), and Prolactin (1365.47). On an MRI of the head examination on April 14, 2021, a solid intrasellar mass of suspected pituitary macroadenoma was found with a size of ± 1.3 cm x 1.4 cm x 1.6 cm.

Conclusion: Secondary amenorrhea caused by hyperprolactinemia due to pituitary macroadenoma is a rare case (40%). First-line therapy for prolactinomas is dopamine agonist administration because most pituitary macroadenomas respond to dopamine agonists.

Downloads

Published

2022-07-27